Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000592528 | SCV000561789 | benign | not provided | 2024-01-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000568751 | SCV000675208 | likely benign | Hereditary cancer-predisposing syndrome | 2017-02-13 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Eurofins Ntd Llc |
RCV000592528 | SCV000704089 | uncertain significance | not provided | 2017-01-16 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000568751 | SCV002535359 | benign | Hereditary cancer-predisposing syndrome | 2021-04-15 | criteria provided, single submitter | curation | |
Prevention |
RCV003960108 | SCV004774511 | likely benign | SMARCB1-related condition | 2019-07-08 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |